Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2007-05-08
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S872000, C514S619000, C514S318000, C514S323000, C514S324000, C514S326000, C514S319000
Reexamination Certificate
active
09985679
ABSTRACT:
The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use.whereinR represents the ring Aor 2-pyridinyl or 2-pyridinyl-N-oxide;R1is selected from halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups;R2and R3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groups;n represents zero, 1 or 2;and pharmaceutically acceptable salts and solvates thereof.
REFERENCES:
patent: 4031226 (1977-06-01), Soudijn et al.
patent: 4066772 (1978-01-01), Vandenberk et al.
patent: 4695578 (1987-09-01), Coates et al.
patent: 4839465 (1989-06-01), Singh et al.
patent: 4886808 (1989-12-01), King
patent: 4906755 (1990-03-01), Gittos
patent: 4920227 (1990-04-01), Pelletier et al.
patent: 5102667 (1992-04-01), Dubroeucq et al.
patent: 5202333 (1993-04-01), Berger et al.
patent: 5321032 (1994-06-01), Matsuo et al.
patent: 5360800 (1994-11-01), Coates et al.
patent: 5360820 (1994-11-01), Hagan et al.
patent: 5538982 (1996-07-01), Hagan et al.
patent: 5547964 (1996-08-01), Hagan et al.
patent: 5576317 (1996-11-01), Gonsalves
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5798363 (1998-08-01), Hagan et al.
patent: 6048859 (2000-04-01), Dorn et al.
patent: 6096742 (2000-08-01), Crocker et al.
patent: 6235735 (2001-05-01), Dorn et al.
patent: 6326383 (2001-12-01), Hagan et al.
patent: 11230/88 (1988-08-01), None
patent: 14134/88 (1988-10-01), None
patent: 0 247 266 (1987-12-01), None
patent: 0 284 942 (1988-10-01), None
patent: 0 327 099 (1989-08-01), None
patent: 0 394 989 (1990-10-01), None
patent: 0 436 334 (1991-07-01), None
patent: 0 446 706 (1991-09-01), None
patent: 0 482 539 (1992-04-01), None
patent: 0 484 719 (1992-05-01), None
patent: 499 313 (1992-08-01), None
patent: 0 522 808 (1993-01-01), None
patent: 0 533 280 (1993-03-01), None
patent: 0 615 751 (1994-09-01), None
patent: 0 627 221 (1994-12-01), None
patent: 0 769 300 (1997-04-01), None
patent: 2 100 259 (1982-12-01), None
patent: 2 152 049 (1985-07-01), None
patent: 2 216 529 (1989-10-01), None
patent: 910819 (1991-09-01), None
patent: 913831 (1992-05-01), None
patent: 60-214784 (1985-10-01), None
patent: 62-252764 (1987-11-01), None
patent: 63-196583 (1988-08-01), None
patent: 3-503768 (1991-08-01), None
patent: WO 90/05729 (1990-05-01), None
patent: WO 91/02745 (1991-03-01), None
patent: WO 91/12266 (1991-08-01), None
patent: WO 91/18016 (1991-11-01), None
patent: WO 92/17449 (1992-10-01), None
patent: 93/00330 (1993-01-01), None
patent: WO 93/00331 (1993-01-01), None
patent: WO 93/01170 (1993-01-01), None
Henry et al. (editors), Substance P and Neurokinins—Springer Verlag 1987, p. XVII-XVIII.
Ekstrom et al., British Journal of Pharmacology, 1988 94(3) 707-712.
Kambam et al., Anaesthesiology 1990, 73(3A), Abstract A10.
Niel,Arch. int. Physiol. Biochim. Biophys., 99, 5, A65-A76, 1991.
Leslie,Neurochem. Int., 7(2) 191-211, 1985.
Andrews et al.,TIPS, 9, 334-341, 1988.
Carpenter et al.,Cell and Mol. Neurobiol., 3(2) 113-126, 1983.
Carpenter et al.,Fed. Prod. Am. Sco. Exp. Biol., 43(15), 2952-2954, 1984.
Saffroy et al.,Peptides, 9, 227-241, 1988.
Tattersall et al.,European Journal of Pharmacology, 250, R5-R6, Nov. 1, 1993.
Bountra et al.,European Journal of Pharmacology, 249, R3-R4, Nov. 1, 1993.
Newton et al.,J. Comp. Neurol., 234, 87-104, 1985.
Proceedings of “Substance P and Neurokinins—Montreal 1986”, A Satellite Symposium of the XXX International Congress of the International Union of Physiological Sciences, J.L. Henry et al., Editors.
Peter Ward et al., J. Med. Chem., 38, pp. 4985-4992 (1995).
David O. Carpenter et al., Cellular and Molecular Neurobiology, 3(2) pp. 113-126 (1983).
A.F. Ghouri et al., Anesthesiology, 73(3A) p. 9 (Sep. 1990).
Domenico Regoli et al., TIPS, 9, pp. 290-295 (Aug. 1988).
P.L.R. Andrews et al., TIPS, 9, pp. 334-341, (Sep. 1988).
Brown et al., Tachykinin Antagonists, Hakanson R. and Sundler, F. (Eds.) Elsevier:Amsterdam, pp. 305-312 (1985).
J.W. Dalley et al., Journal of Psychopharmacology, 4(4), p. 285, 1990 (Abstract).
David O. Carpenter et al., Final Report No. USAFSAM-TR-83-41, Peptide-Induced Emesis in Dogs, Oct. 1983.
T.D. Walsh et al., The Pharmaceutical Journal, pp. 525-527 (Oct. 29, 1983).
Vincent Gotz et al., On Continuing Practice, 8(4), pp. 11-20 (1981).
Shinya Ueno et al., Life Sciences, 41(4), pp. 513-518 (1987).
Shinya Ueno et al., Life Sciences, 43(5), pp. 413-420 (1988).
G. A. Saab, Am J Clin Oncol, 11(4), pp. 470-473 (1988).
Kathryn Louise Wood, Ph.D. Thesis, Univ. London, 1988, paragraphs 2.5 and 2.7.
R.A. Leslie, Neurochem. Int., 7(2), pp. 191-211 (1985).
David O. Carpenter et al., Final Report No. USAFSAM-TR-82-28, USAF School of Aerospace Medicine, 1982, paragraph 2.8.
J.P. Miolan et al., Neuropeptides, 12, pp. 243-248 (1988).
V.V. Yasnetsov et al., Byulleten Eksperimentalnoi Biologii I Meditsiny, 103(5), pp. 586-588 (May 1987) (Translation).
V.S. Shashkov et al., Farmakologiia I Toksikologiia, 51(2), pp. 30-36, (Mar.-Apr. 1988) (Translation).
Yu. V. Drozd et al., Byulleten Eksperimentalnoi Biologii I Meditsiny, 106(7), pp. 50-52 (1988) (Translation).
V.V. Yasnetsov et al., Kosmicheskaia Biologii I Aviakosmicheskaia Meditsina, 22(2) pp. 72-73 (1988) (Translation).
R. Michael Snider et al., Science, Reports, pp. 435-437, (Jan. 25, 1991).
Patrick W. Mantyh, J. Clin. Psychiatry, 63, Suppl. 11, pp. 6-10, (2002).
Dan L. Longo et al., Cancer Treatment Reports, 66(11), pp. 1975-1976 (Nov. 1982).
Nicolas Tsavaris et al., Journal of Pain and Symptom Management, 6(8), pp. 461-465, Nov. 1991.
Merck Index, 11thEd, p. 1082 (1989).
New Compendium of Internal Medicine, 1, pp. 281-294 (1975).
New Compendium of Internal Medicine, 6, pp. 173-188 (1977).
Brain & Nerve, 20, pp. 959-963 (1968) (with English abstract).
Dam et al., Peptides, (7), pp. 855-864 (1986).
Butler, A., et al., Pharmacological Properties of GR 38032F, a novel antagonist at 5-HT3receptors, British Journal of Pharmacology, 94(2), pp. 397-412 (1988).
Bradley et al., “Proposal for the Classification and Nomenclature of Functional Receptors for 5-hydroxytryptamine,” Neuropharmacology, 25(6), pp. 563-576 (1986).
Dutta, A.S., “Tachykinin Receptors”. Comprehensive Medicinal Chemistry, 3, pp. 1001-1022, Ed. Emmett, J.C. (1990).
J. Fozard et al., Blockade of Neuronal Tryptamine Receptors by Metoclopramide, European Journal of Pharmacology, 49, pp. 109-112 (1978).
J. Fozard et al., Blockade of Serotonin Receptors on Autonomic Neurones by (-) Cocaine and Some Related Compounds, European Journal of Pharmacology, 59, pp. 195-210 (1979).
Mark-up Copy of EP 0 533 280 B1 for European Opposition Proceeding.
Decision by the European Patent Office on Opposition Proceedinds on EP 0533280 B1.
Minutes of the Oral Proceedings Before the Opposition Division dated Apr. 2, 2004.
Physicians' Desk Reference, PDR® Elctronic Library™, PDR Entry for ALOXI® (Palonosetron), printed from website an Aug. 11, 2004.
Office Action issued by the Europen Patent Office on Oct. 27, 2003, in coresponding European Application No. 99 200 337.6-2107.
Introduction to Pharamcology, New Edition, 1981, Nanzandoh Co., Ltd.:Tokyo, Japan, p. 7.
Merck Index, 11thed. (1989) p. 6802, Ondansetron.
Seyfried C.A. et al.,Drug Metabolism and Drug Interactions, vol. 9, No. 2, pp. 149-160, 1991.
L. Grélot et al.,British Journal of Pharmacology(1998) 124, 1643-1650.
Watson et al.,British Jourrnal of Pharmacology115, 84-94 (1995).
Gonsalves et al.,European Journal of Pharmocology305, 181-185 (1996).
Gardner et al.,Regulatory Peptides65, 45-53 (1996).
Singh et al.,European Journal of Pharmacology321, 209-216 (1997).
Gardner et al.,Neuropharmacology37, 1643-1644 (1998).
Tattersall et al.,Neuropharmacology39, 652-663 (2000).
Tsu
Bunce Keith Thomas
Hagan Russell Michael
Glaxo Group Limited
Wang Shengjun
LandOfFree
Medical use for tachykinin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical use for tachykinin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical use for tachykinin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792404